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Preface Probiotics and prebiotics have received increasing attention over the past few decades as ways to increase the health of the host. The definitions of both probiotics and prebiotics include a 'health benefit for the host' , which is why regulatory bodies do not allow the use of the phrases on commercial products. These organizations are not (yet) convinced by the ever growing evidence that shows the benefit of the exogenous beneficial microbes (probiotics) or the compounds (prebiotics) that selectively increase the numbers and/or activity of the endogenous beneficial microbes in our gut. Despite the reservation by regulatory bodies to allow the use of these words, scientists still use the phrases in scientific publications when a benefit to the host has been shown. Significant advances have been made in recent years in the development of products with probiotics and/or prebiotics to prevent numerous diseases and disorders. Here, after a brief introduction to the field, first the different probiotic genera are discussed. Next, topics related to prebiotics are highlighted. Furthermore, effects of probiotics and prebiotics on health are included, focusing on areas in which these dietary ingredients have recently been used. Finally, an outlook to the future is given. The contributions take a critical view on the evidence for health benefits of probiotics and prebiotics. The authors are believers, although we remain critical about certain aspects of the research, such as dose, duration of intake, combinations of probiotics, and combination of probiotics with prebiotics. Nevertheless, we believe there is a future for these health beneficial components of the diet as natural ways to combat the diseases and disorders that perturb our modern society. Koen Venema and Ana Paula do Carmo caister.com/probiotics -an on-line resource riboromal RNA (both large and small unit rRNA) sequence data • http://rdp.cme.msu.edu/RDP:
-an on-line resource riboromal RNA (both large and small unit rRNA) sequence data • http://greengenes.lbl.gov/cgi-bin/nph-index.cgi:
-a web application providing access to the greengenes 16S rRNA gene sequence alignment for browsing, blasting, probing, and downloading • http://www.hmpdacc.org/:
-stores all the protocols, computational methods, and the results produced by the Human Microbiome Project.
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